By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Genzyme Corp. v. Impax Laboratories, Inc.
1:09-cv-00846; filed April 3, 2009 in the District Court of Maryland
Infringement of U.S. Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September 16, 1997) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Genzyme's Renvela® (sevelamer carbonate, used for the control of serum phosphorus in patients with chronic kidney disease on dialysis). View the complaint here.
Abbott Laboratories et al. v. Sandoz Inc. et al.
1:09-cv-00215; filed April 1, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,246,925 ("19-nor-Vitamin D Compounds for Use in Treating Hyperparathyroidism," issued September 21, 1993), 5,587,497 ("19-nor-Vitamin D Compounds," issued December 24, 1996), 6,136,799 ("Cosolvent Formulations," issued October 24, 2000), and 6,361,758 (same title, issued March 26, 2002) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure). View the complaint here.
Shire Canada Inc. et al. v. Natco Pharma Ltd.
1:09-cv-03165; filed April 1, 2009 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,968,976 ("Pharmaceutical Composition Containing Selected Lanthanum Carbonate Hydrates," issued October 19, 1999) and 7,381,428 ("Stabilized Lanthanum Carbonate Compositions," issued June 3, 2008) following a Paragraph IV certification as part of Natco's filing of an ANDA to manufacture a generic version of Shire's Fosrenol® (lanthanum carbonate chewable tablets, used for the reduction of serum phosphate in patients with end stage renal disease). View the complaint here.
Millennium Pharmaceuticals Inc. et al. v. Teva Parenteral Medicines Inc. et al.
1:09-cv-00204; filed March 27, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,747,447 ("Stable Polypeptide Composition," issued May 5, 1998) and 5,968,902 ("Platelet Aggregation Inhibitors," issued October 19, 1999), licensed to Schering Corp., following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Schering-Plough's Integrilin® (eptifibatide injection, used to treat acute coronary syndrome). View the complaint here.
Comments